Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K/AKT/mTOR pathway
Yixuan Wang, Qing Xia, Xinjia Wang, Yiwei Lu, Shizhuo Wang, Yisheng Jiao · 2025
Read Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K/AKT/mTOR pathway by Yixuan Wang, Qing Xia, Xinjia Wang, Yiwei Lu, Shizhuo Wang, Yisheng Jiao (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12903312.txt.
Description
Yixuan Wang and co-authors review how to make a class of cancer drugs work in more ovarian tumors in this 2025 paper. PARP inhibitors transformed care for tumors that cannot repair DNA well, such as those with BRCA faults. Most ovarian cancers repair DNA fine, and the drugs stall there.
The review gathers evidence on a partner target: a growth pathway that also helps cells answer DNA damage and is often overactive in this cancer. Blocking that pathway can leave tumor cells less able to repair, widening the PARP drugs' reach. Studies in cells, animals, and early trials support the pairing, with natural and lab-made blockers and even nanoparticle delivery showing promise. Biomarker-guided trials are sorting out which patients gain most. The authors see the combination as the route to broader benefit in a hard cancer.
Catalog record
| CREATOR | Yixuan Wang, Qing Xia, Xinjia Wang, Yiwei Lu, Shizhuo Wang, Yisheng Jiao |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 143 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |